Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis

The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients

(2015) T. Powrózek et al.   Clinical & Translational Oncology

Candidate pathway-based genetic association study of platinum and platinum–taxane related toxicity in a cohort of primary lung cancer patients

(2015) Cassandra Johnson et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy

(2015) S Cao et al.   PHARMACOGENOMICS JOURNAL

Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity

(2015) Juan Chen et al.   TUMOR BIOLOGY

Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy

(2015) Jung Ran Choi et al.   Cancer Research and Treatment

Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients

(2014) Fenglei Wu et al.   Cancer Epidemiology

Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection

(2014) Nigel Stallard et al.   Journal of Biopharmaceutical Statistics

Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine

(2014) Xiaoxia Chen et al.   MEDICAL ONCOLOGY

Quality of life during chemotherapy in lung cancer patients: results across different treatment lines

(2013) L M Wintner et al.   BRITISH JOURNAL OF CANCER

Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions

(2012) John D Clarke et al.   Expert Opinion on Drug Metabolism & Toxicology

Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues

(2012) Johanna Hasmats et al.   GENE

Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients

(2012) Xiaojing Xu et al.   LUNG CANCER

Using companion and coupled diagnostics within strategy to personalize targeted medicines

(2012) Donald RJ Singer et al.   Personalized Medicine

A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer

(2012) J-Y Han et al.   PHARMACOGENOMICS JOURNAL

The NICE Diagnostics Assessment Programme

(2012) Nick Crabb et al.   Health Policy and Technology

Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients

(2010) Emiko Sugiyama et al.   CLINICAL PHARMACOKINETICS

Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study

(2010) Araba A. Adjei et al.   Journal of Thoracic Oncology

Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue

(2010) Swati S. More et al.   MOLECULAR CANCER THERAPEUTICS

Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors

(2009) R. L. Oostendorp et al.   DRUG METABOLISM AND DISPOSITION

Ethnic differences in drug metabolism and toxicity from chemotherapy

(2009) Viet Hong Phan et al.   Expert Opinion on Drug Metabolism & Toxicology

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

(2009) Anne T. Nies et al.   HEPATOLOGY

Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics

(2009) Federico Innocenti et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

(2009) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY

Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression

(2009) Pei-Chieng Cha et al.   JOURNAL OF HUMAN GENETICS

Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia

(2008) Kazuma Kiyotani et al.   CANCER SCIENCE

Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials

(2008)   JOURNAL OF CLINICAL ONCOLOGY

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer

(2008) Ji-Youn Han et al.   LUNG CANCER

The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate Carrier

(2008) R. Zhao et al.   MOLECULAR PHARMACOLOGY

Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney

(2008) Zoulikha M Zaïr et al.   PHARMACOGENOMICS

Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer

(2007) Ji-Youn Han et al.   LUNG CANCER